articleThe LancetJan 1, 2010Closed access

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

Fondazione IRCCS Istituto Nazionale dei Tumori · Olgahospital · +12 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,264
total citations
FWCI
48.20
Percentile
100%
References
36
Citations per year

Authors

20

Topics & keywords

Keywords
  • Trastuzumab
  • Medicine
  • Breast cancer
  • Oncology
  • Internal medicine
  • Regimen
  • Chemotherapy
  • Hazard ratio
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.